After spending more than two years in stealth mode, Sionna Therapeutics is unveiling with $111 million in series B funds to catapult its cystic fibrosis pipeline and take on market leader Vertex ...
Two biotechnology startups on Friday revealed plans to launch initial public offerings, extending a step-up in IPO activity among privately held drug companies. Sionna Therapeutics is working on ...
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company’s first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy ...
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics (SION), Inc. , a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic ...
Following these transactions, the involved parties now hold a total of 6,684,962 shares of Sionna Therapeutics' common stock. This strategic move reflects TPG's continued interest and investment in ...
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results